The therapeutic potential of CRF1 antagonists for anxiety

Bibliography

• KESSLER RC, McGONAGLE KA, ZHAO S et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8–19.
   PubMed Web of Science ®Google Scholar
• DUPONT RL, RICE DP, MILLER LS et al.: Economic costs of anxiety disorders. Anxiety (1996) 2:167–172.
   PubMedGoogle Scholar
• LEPINE JP: The epidemiology of anxiety disorders: prevalence and societal costs. Clin. Psychiatry (2002) 63\(Suppl. 14):4–8.
   Google Scholar
• KENDLER KS, DAVIS CG, KESSLER RC: The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. Br. .1. Psychiatry (1997) 170:541–548.
   PubMed Web of Science ®Google Scholar
• WITTCHEN HU, ZHAO S, KESSLER RC, EATON WW: DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:355–364.
   PubMed Web of Science ®Google Scholar
• JUDD LL, KESSLER RC, PAULUS MP et al.: Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiam. Scand. Suppl. (1998) 393:6–11.
   PubMedGoogle Scholar
• GOODWIN RD, STAYNER DA, CHINMAN MJ et al.: The relationship between anxiety and substance use disorders among individuals with severe affective disorders. Comm: Psychiatry (2002) 43:245–252.
   PubMed Web of Science ®Google Scholar
• SEWELL MC, GOGGIN KJ, RABKINJGet al.: Anxiety syndromes and symptoms among men with AIDS: a longitudinal controlled study. Psychosomatics (2000) 41:294–300.
   Google Scholar
• McWILLIAMS LA, COX BJ, ENNS MW:Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain (2003) 106:127–133.
   PubMed Web of Science ®Google Scholar
• GOODWIN RD, STEIN MB: Generalized anxiety disorder and peptic ulcer disease among adults in the United States. Psychosom. Med. (2002) 64:862–866.
   PubMed Web of Science ®Google Scholar
• LECRUBIER Y: The burden of depression and anxiety in general medicine. J. Clin. Psychiatry (2001) 62\(Suppl. 8):4–9.
   Google Scholar
• STEIN MB: Attending to anxiety disorders in primary care. I Clin. Psychiatry (2003) 64\(Suppl. 15):35–39.
   Google Scholar
• GREENBERG PE, SISITSKY T, KESSLER RC et al: The economic burden of anxiety disorders in the 1990s. Clin. Psychiatry (1999) 60:427–435.
   PubMed Web of Science ®Google Scholar
• RICE DP, MILLER LS: Health economics and cost implications of anxiety and other mental disorders in the United States. Br. J. Psychiatry Sapp]. (1998) 34:4–9.
   Google Scholar
• WITTCHEN HU: Generalized anxiety disorder: prevalence, burden, and cost to society. Depress. Anxiety (2002) 16:162–171.
   PubMed Web of Science ®Google Scholar
• KHAN A, LEVENTHAL RM, KHAN S, BROWN WA: Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database.' Affect. Disord. (2002) 68:183–190.
   PubMed Web of Science ®Google Scholar
• ALLGULANDER C: Suicide and mortalitypatterns in anxiety neurosis and depressive neurosis. Arch. Gen. Psychiatry (1994) 51:708–712.
   PubMed Web of Science ®Google Scholar
• ALLGULANDER C, LAVORI PW: Excess mortality among 3302 patients with 'pure' anxiety neurosis. Arch. Gen. Psychiatry (1991) 48:599–602.
   PubMed Web of Science ®Google Scholar
• MENDLOWICZ MV, STEIN MB: Quality of life in individuals with anxiety disorders. Am. J. Psychiatry (2000) 157:669–682.
   PubMed Web of Science ®Google Scholar
• YOUNG AS, KLAP R, SHERBOURNE CD, WELLS KB: The quality of care for depressive and anxiety disorders in the United States. Arch. Gen. Psychiatry (2001) 58:55–61.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ BF, WEISBERG RB, PAGANO ME et al.: Mental health treatment received by primary care patients with posttraumatic stress disorder. J. Psychiatry (2003) 64:1230–1236.
   Google Scholar
• BALLENGER JC, DAVIDSON JR, LECRUBIER Y et al.: Consensus statement on social anxiety disorder from the International Consensus Group on Depression Anxiety. I Clin. Psychiatry (1998) 59\(Suppl. 17):54–60.
   Google Scholar
• BALLENGER JC, DAVIDSON JR, LECRUBIER Y et al.: Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression Anxiety. I Clin. Psychiatry (2001) 62\(Suppl. 11):53–58.
   Google Scholar
• BALLENGER JC, DAVIDSON JR, LECRUBIER Y et al.: Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression Anxiety. I Clin. Psychiatry (2000) 61\(Suppl. 5):60–66.
   Google Scholar
• JENIKE MA: Clinical practice. Obsessive-compulsive disorder. N Engl. I Med. (2004) 350:259–265.
   PubMed Web of Science ®Google Scholar
• WOODS JH, KATZ JL, WINGER G: Benzodiazepines: use, abuse, and consequences. Pharmacol. Rev. (1992) 44:151–347.
   PubMed Web of Science ®Google Scholar
• �A thorough review on the clinical use and abuse liability of benzodiazepines.
   Google Scholar
• DE SOUZA EB: Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology (1995) 20:789–819.
   PubMed Web of Science ®Google Scholar
• KOOB GF, HEINRICHS SC: A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. (1999) 848:141–152.
   PubMed Web of Science ®Google Scholar
• VALE W, SPIESS J, RIVIER C, RIVIER J: Characterization of a 41-residue ovine
   Google Scholar
• �� hypothalamic peptide that stimulates secretion of corticotropin and 13-endorphin. Science (1981) 213:1394-1397. Initial identification of CRE
   Google Scholar
• VAUGHAN J, DONALDSON C, BITTENCOURT J et al.: Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (1995) 378:287–292.
   PubMed Web of Science ®Google Scholar
• �Initial identification of urocortin 1.
   Google Scholar
• REYES TM, LEWIS K, PERRIN MH et al.: Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by Type 2 CRF receptors. Proc. Nati Acad. Sci USA (2001) 98:2843–2848.
   PubMed Web of Science ®Google Scholar
• �Initial identifications of the urocortin 2 prohormone.
   Google Scholar
• LEWIS K, LI C, PERRIN MH et al: Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Nati Acad. Sci.USA (2001) 98:7570–7575.
   PubMed Web of Science ®Google Scholar
• �One of two initial identifications of the urocortin 3 prohormone.
   Google Scholar
• HSU SY, HSUEH AJ: Human stresscopin and stresscopin-related peptide are selective ligands for the Type 2 corticotropin-releasing hormone receptor. Nat Med. (2001) 7:605–611.
   PubMed Web of Science ®Google Scholar
• �One of two initial identifications of the urocortin 3 prohormone.
   Google Scholar
• ZORRILLA EP, TACHE Y, KOOB GF: Nibbling at CRF receptor control of feeding and gastrocolonic motility. Trends Pharmacol. Sci. (2003) 24:421–427.
   PubMed Web of Science ®Google Scholar
• �A recent review of the roles of CRF receptor systems in feeding and gastrointestinal function.
   Google Scholar
• PERRIN MH, VALE WW: Corticotropin releasing factor receptors and their ligand family. Ann. NY Acad. Sci. (1999) 885:312–328.
   PubMed Web of Science ®Google Scholar
• OWENS MJ, NEMEROFF CB: Corticotropin-releasing factor antagonists in affective disorders. Expert Opin. Investig. Drugs. (1999) 8:1849–1858.
   PubMedGoogle Scholar
• HAUGER RL, GRIGORIADIS DE, DALLMAN MF et al.: International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev (2003) 55:21–26.
   Google Scholar
• ��Consensus nomenclature and concisereview of the CRF/urocortin signalling systems.
   Google Scholar
• DAUTZENBERG FM, KILPATRICK GJ, HAUGER RL, MOREAU J: Molecular biology of the CRH receptors- in the mood. Peptides. (2001) 22:753–760.
   PubMed Web of Science ®Google Scholar
• HARMAR AJ: Family-B G-protein-coupledreceptors. Genome Biol (2001) 2(12):REVIEWS3013.
   Google Scholar
• DAUTZENBERG FM, PY-LANG G, HIGELIN J et al: Different binding modes of amphibian and human corticotropin-releasing factor Type 1 and Type 2 receptors: evidence for evolutionary differences.' Pharmacol. Exp. Then (2001) 296:113–120.
   PubMed Web of Science ®Google Scholar
• BEHAN DP, GRIGORIADIS DE, LOVENBERG T et al: Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry (1996) 1:265–277.
   PubMed Web of Science ®Google Scholar
• �An excellent review of the biology and relevance of the CRF-BP.
   Google Scholar
• ORTH DN, MOUNT CD: Specific high-affinity binding protein for human corticotropin-releasing hormone in normal human plasma. Biochem. Biophys. Res. Commun. (1987) 143:411–417.
   PubMed Web of Science ®Google Scholar
• BEHAN DP, LINTON EA, LOWRY PJ: Isolation of the human plasma corticotrophin-releasing factor-binding protein. J. Endocrinol (1989) 122:23–31.
   PubMed Web of Science ®Google Scholar
• SUTTON SW, BEHAN DP, LAHRICHI SL et al: Ligand requirements of the human corticotropin-releasing factor-binding protein. Endocrinol (1995) 136:1097–1102.
   PubMed Web of Science ®Google Scholar
• BAIGENT SM, LOWRY PJ: Urocortin isthe principal ligand for the corticotrophin-releasing factor binding protein in the ovine brain with no evidence for a sauvagine-like peptide.' Mol. Endocrinol. (2000) 24:53–63.
   Web of Science ®Google Scholar
• BEHAN DP, DE SOUZA EB, LOWRY PJ et al.: Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front. Neuroendocrinology (1995) 16:362–382.
   PubMed Web of Science ®Google Scholar
• KEMP CF, WOODS RJ, LOWRY PJ: The corticotrophin-releasing factor-binding protein: an act of several parts. Peptides. (1998) 19:1119–1128.
   PubMed Web of Science ®Google Scholar
• CHAN RK, VALE WW, SAWCHENKO PE: Paradoxical activational effects of a corticotropin-releasing factor-binding protein `ligand inhibitor' in rat brain. Neurosci. (2000) 101:115–129.
   PubMed Web of Science ®Google Scholar
• JAHN 0, ECKART K, SYDOW S, HOFMANN BA, SPIESS J: Pharmacological characterization of recombinant rat corticotropin releasing factor binding protein using different sauvagine analogs. Peptides (2001) 22:47–56.
   PubMed Web of Science ®Google Scholar
• WEBSTER EL, LEWIS DB, TORPY DJ et al.: In vivo and M vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinol. (1996) 137:5747–5750.
   PubMed Web of Science ®Google Scholar
• SMITH GW, AUBRYJM, DELLU F et al: Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 20:1093–1102.
   PubMed Web of Science ®Google Scholar
• ��One of the first two reports to reveal theanxiolytic-like phenotype of CRF1-deficient mice.
   Google Scholar
• BRUHN TO, SUTTON SW, PLOTSKY PM, VALE WW: Central administration of corticotropin-releasing factor modulates oxytocin secretion in the rat. Endocrinol (1986) 119:1558–1563.
   PubMed Web of Science ®Google Scholar
• BROWN MR, RIVIER C, VALE W: Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinol (1984) 114:1546–1549.
   PubMed Web of Science ®Google Scholar
• VENIHAKI M, MAJZOUB J: Lessons from CRH knockout mice. Neuropeptides (2002) 36:96–102.
   PubMed Web of Science ®Google Scholar
• VETTER DE, LI C, ZHAO L et al.: Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat. Genet. (2002) 31:363–369.
   PubMed Web of Science ®Google Scholar
• �A reported phenotype of urocortin 1-deficient mice.
   Google Scholar
• TURNBULL AV, VAUGHAN J, RIVIER JE, VALE WW, RIVIER C: Urocortin is not a significant regulator of intermittent electrofootshock-induced adrenocorticotropin secretion in the intact male rat. Endocrinol. (1999) 140:71–78.
   PubMed Web of Science ®Google Scholar
• HARA Y, UETA Y, ISSE T et al.: Increase ofurocortin-like immunoreactivity in the rat supraoptic nucleus after dehydration but not food deprivation. Neurosci. Lett. (1997) 229:65–68.
   PubMed Web of Science ®Google Scholar
• DAUTZENBERG FM, HAUGER RL: The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. (2002) 23:71–77.
   PubMed Web of Science ®Google Scholar
• �� Concise review of the biology of recently identified CRF/urocortin signalling components, including the type 2 urocortins.
   Google Scholar
• SANCHEZ MM, YOUNG LJ, PLOTSKY PM, INSEL TR: Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. Comp. Neurol (1999) 408:365–377.
   PubMed Web of Science ®Google Scholar
• ��Thorough description of the distributionof CRF receptor binding and synthesis in non-human primate brain.
   Google Scholar
• VAN PETT K, VIAU V, BITTENCOURT JC et al.: Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. I Comp. Neurol (2000) 428:191–212.
   PubMed Web of Science ®Google Scholar
• ��Thorough description of the distributionof CRF synthesis in rat and mouse brain and pituitary.
   Google Scholar
• CHALMERS DT, LOVENBERG TW, GRIGORIADIS DE, BEHAN DP, DE SOUZA EB: Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci. (1996) 17:166–172.
   PubMed Web of Science ®Google Scholar
• POTTER E, SUTTON S, DONALDSON C et al.: Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc. Natl Acad. Sci. USA (1994) 91:8777–8781.
   PubMed Web of Science ®Google Scholar
• KOSTICH WA, CHEN A, SPERLE K, LARGENT BL: Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2-7 receptor. Ma Endocrinol (1998) 12:1077–1085.
   PubMed Web of Science ®Google Scholar
• CHARLTON BG, FERRIER IN, PERRY RH: Distribution of corticotropin-releasing factor-like immunoreactivity in human brain. Neuropeptides (1987) 10:329–334.
   PubMed Web of Science ®Google Scholar
• CHAPPELL PB, SMITH MA, KILTS CD et al.: Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. Neurosci. (1986) 6:2908–2914.
   PubMed Web of Science ®Google Scholar
• MERCHENTHALER I, VIGH S, PETRUSZ P, SCHALLY AV: Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Amj Anat. (1982) 165:385–396.
   PubMedGoogle Scholar
• MERCHENTHALER I: Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides (1984) 5\(Suppl. 1):53–69.
   Google Scholar
• SWANSON LW, SAWCHENKO PE, RIVIER J, VALE WW: Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology (1983) 36:165–186.
   PubMed Web of Science ®Google Scholar
• PALKOVITS M, BROWNSTEIN MJ, VALE W: Distribution of corticotropin-releasing factor in rat brain. Fed. Proc (1985) 44:215–219.
   PubMedGoogle Scholar
• ZORRILLA EP, KOOB GF, The roles of urocortins 1, 2 and 3 in the brain. In: Techniques M the Behavioral and Neural Sciences (Volume la). Handbook of Stress, Immunology and Behaviour. T Steckler, N Kafiri, H Reul (Eds) Elsevier Science, New York (2004).
   Google Scholar
• �Comprehensive review of the pharmacology, distribution and functional significance of brain urocortins.
   Google Scholar
• SMAGIN GN, HEINRICHS SC, DUNN AJ: The role of CRH in behavioral responses to stress. Peptides. (2001) 22:713–724.
   PubMed Web of Science ®Google Scholar
• DUNN AJ, BERRIDGE CW: Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brunt Res. Rev (1990) 15:71–100.
   Google Scholar
• EHLERS CL, HENRIKSEN SJ, WANG Met al.: Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brunt Res. (1983) 278:332–336.
   Google Scholar
• EHLERS CL: EEG stability following corticotropin releasing factor in rats. Psychoneuroendocrinology (1986) 11:121–125.
   PubMed Web of Science ®Google Scholar
• WEISS SR, POST RM, GOLD PW et al.: CRF-induced seizures and behavior: interaction with amygdala kindling. Brunt Res. (1986) 372:345–351.
   PubMed Web of Science ®Google Scholar
• MARROSU F, FRATTA W, CARCANGIU P, GIAGHEDDU M, GESSA GL: Localized epileptiform activity induced by murine CRF in rats. Epilepsia (1988) 29:369–373.
   PubMed Web of Science ®Google Scholar
• BARAM TZ, SCHULTZ L: Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Brunt Res. Dev. Brain Res. (1991) 61:97–101.
   PubMedGoogle Scholar
• SLAWECKI CJ, SOMES C, RIVIERJE, EHLERS CL: Neurophysiological effects of intracerebroventricular administration of urocortin. Peptides (1999) 20:211–218.
   PubMed Web of Science ®Google Scholar
• BARAM TZ, CHALMERS DT, CHEN C, KOUTSOUKOS Y, DE SOUZA EB: The CREi receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. (1997) 770:89–95.
   PubMed Web of Science ®Google Scholar
• SCHULZ DW, MANSBACH RS, SPROUSE J et al: CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. ScLUSA (1996) 93:10477–10482.
   PubMed Web of Science ®Google Scholar
• ��First reported in vivo characterisation of asmall-molecule CRF1 receptor antagonist.
   Google Scholar
• OKUYAMA S, CHAKI S, KAWASHIMA N et al: Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. I Pharmacol Exp. The]: (1999) 289:926–935.
   Google Scholar
• SUTTON RE, KOOB GE LE MOAL M, RIVIERJ, VALE W: Corticotropin releasing factor produces behavioural activation in rats. Nature (1982) 297:331–333.
   PubMed Web of Science ®Google Scholar
• KOOB GF, THATCHER-BRITTON K: Stimulant and anxiogenic effects of corticotropin releasing factor. Frog. Clin. Biol. Res. (1985) 192:499–506.
   PubMedGoogle Scholar
• �First identification of the behavioural arousing effects of central CRF infusion.
   Google Scholar
• SPINA M, MERLO-PICH E, CHAN RK et al.: Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science. (1996) 273:1561–1564.
   PubMed Web of Science ®Google Scholar
• KALIN NH, SHELTON SE, KRAEMER GW, McKINNEY WT: Corticotropin-releasing factor administered intraventricularly to rhesus monkeys. Peptides (1983) 4:217–220.
   PubMed Web of Science ®Google Scholar
• WINSLOW JT, NEWMAN JD, INSEL TR: CRH and alpha-helical-CRH modulate behavioral measures of arousal in monkeys. Pharmacol Biochem. Behav. (1989) 32:919–926.
   PubMed Web of Science ®Google Scholar
• JOHNSON RW, VON BORELL EH, ANDERSON LL, KOJIC LD, CUNNICK JE: Intracerebroventricular injection of corticotropin-releasing hormone in the pig: acute effects on behavior, adrenocorticotropin secretion, and immune suppression. Endocrinol (1994) 135:642–648.
   PubMed Web of Science ®Google Scholar
• SALAK-JOHNSON JL, McGLONE JJ, WHISNANT CS, NORMAN RL, KRAELING RR: Intracerebroventricular porcine corticotropin-releasing hormone and cortisol effects on pig immune measures and behavior. Physic] Behav. (1997) 61:15–23.
   PubMed Web of Science ®Google Scholar
• PARROTT RE VELLUCCI SV: Behaviour of pigs given corticotrophin-releasing hormone in combination with flumazenil or diazepam. Pharinacol Biochein. Behav. (2000) 67:465–471.
   PubMed Web of Science ®Google Scholar
• PARROTT RE VELLUCCI SV, GOODE JA: Behavioral and hormonal effects of centrally injected `amdogenic' neuropeptides in growing pigs. Pharinacol Biochein. Behav. (2000) 65:123–129.
   PubMed Web of Science ®Google Scholar
• OPP M, OBAL F Jr, KRUEGER JM: Corticotropin-releasing factor attenuates interleukin 1-induced sleep and fever in rabbits. Arn. Physiol (1989) 257:R528–R535.
   PubMed Web of Science ®Google Scholar
• DUNN AJ, BERRIDGE CW: Corticotropin-releasing factor administration elicits a stress-like activation of cerebral catecholaminergic systems. Pharinacol Biochein. Behav. (1987) 27:685–691.
   PubMed Web of Science ®Google Scholar
• DUNN AJ, BERRIDGE CW, LAI YI, YACHABACH TL: CRF-induced excessive grooming behavior in rats and mice. Peptides (1987) 8:841–844.
   PubMed Web of Science ®Google Scholar
• ZHANG R, NAKANISHI T, OHGUSHI A et al.: Interaction of corticotropin-releasing factor and glucagon-like peptide-1 on behaviors in chicks. Eur. Pharinacol (2001) 430:73–78.
   PubMed Web of Science ®Google Scholar
• OHGUSHI A, BUNGO T, SHIMOJO M et al.: Relationships between feeding and locomotion behaviors after central administration of CRF in chicks. Physiol Behav. (2001) 72:287–289.
   PubMed Web of Science ®Google Scholar
• CLEMENTS S, SCHRECK CB, LARSEN DA, DICKHOFF WW: Central administration of corticotropin-releasing hormone stimulates locomotor activity in juvenile chinook salmon (Oncorhyrichus tshawytscha). Gen. Comp. Endocrinol (2002) 125:319–327.
   PubMed Web of Science ®Google Scholar
• LOWRY CA, BURKE KA, RENNER KJ, MOORE FL, ORCHINIK M: Rapid changes in monoamine levels following administration of corticotropin-releasing factor or corticosterone are localized in the dorsomedial hypothalamus. Harm. Behav. (2001) 39:195–205.
   PubMed Web of Science ®Google Scholar
• LOWRY CA, MOORE FL: Corticotropin-releasing factor (CRF) antagonist suppresses stress-induced locomotor activity in an amphibian. Herm. Behav. (1991) 25:84–96.
   PubMed Web of Science ®Google Scholar
• LOWRY CA, DEVICHE P, MOORE FL: Effects of corticotropin-releasing factor (CRF) and opiates on amphibian locomotion. Bradt Res. (1990) 513:94–100.
   PubMed Web of Science ®Google Scholar
• VALDEZ GR, INOUE K, KOOB GF et al.: Human urocortin II: Mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Bradt Res. (2002) 943:142–150.
   PubMed Web of Science ®Google Scholar
• �A report that intracerebroventricular urocortin 2 infusion lacks the anxiogenic-like and behavioural arousing properties of ovine CRF, suggesting that the CRF2 receptor subserves different behavioural functions to the anxiogenic-like CU' receptor.
   Google Scholar
• VALDEZ GR, ZORRILLA EP, RIVIER J, VALE WW, KOOB GF: Locomotor suppressive and amdolytic-like effects of urocortin 3, a highly selective Type 2 corticotropin-releasing factor agonist. Biabi Res. (2003) 980:206–212.
   Google Scholar
• �A report that intracerebroventricular urocortin 3 infusion has anxiolytic-like effects and lacks the behavioural arousing properties of ovine CRF, further supporting the hypothesis that the CRF2 receptor subserves different behavioural functions than the anxiogenic-like CU' receptor.
   Google Scholar
• CONTARINO A, DELLU F, KOOB GF et al.: Dissociation of locomotor activation and suppression of food intake induced by CRF in CRER1-deficient mice. Endocrinol (2000) 141:2698–2702.
   PubMed Web of Science ®Google Scholar
• ZORRILLA EP, VALDEZ GR, NOZULAK J, KOOB GE MARKOU A: Effects of antalarmin, a CRF Type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. (2002) 952:188–199.
   PubMed Web of Science ®Google Scholar
• MOREAU JL, KILPATRICK G, JENCK F: Urocortin, a novel neuropeptide with amdogenic-like properties. Neurcreport (1997) 8:1697–1701.
   PubMed Web of Science ®Google Scholar
• JONES DN, KORTEKAAS R, SLADE PD, MIDDLEMISS DN, HAGAN JJ: The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology (1998) 138:124–132.
   PubMed Web of Science ®Google Scholar
• SPINA MG, MERLO-PICH E, AKWA Y et al.: Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology (2002) 160:113–121.
   PubMed Web of Science ®Google Scholar
• BALDWIN HA, RASSNICK S, RIVIERJ, KOOB GE BRITTON KT: CRF antagonist reverses the `anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology (1991) 103:227–232.
   PubMed Web of Science ®Google Scholar
• MOMOSE K, INUI A, ASAKAWA A et al: Intracerebroventricularly administered corticotropin-releasing factor inhibits food intake and produces anxiety-like behaviour at very low doses in mice. Diabetes Obes. Metab. (1999) 1:281–284.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI LK, KALIN NH, VANDEN BURGT JA, SHERMAN JE: Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav. Neurosci. (1989) 103:648–654.
   PubMed Web of Science ®Google Scholar
• YANG XM, GORMAN AL, DUNN AJ: The involvement of central noradrenergic systems and corticotropin- releasing factor in defensive-withdrawal behavior in rats. Pharmacol Exp. Titer. (1990) 255:1064–1070.
   PubMed Web of Science ®Google Scholar
• BERRIDGE CW, DUNN AJ: CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacol Biochem. Behav. (1989) 34:517–519.
   PubMed Web of Science ®Google Scholar
• BRITTON KT, MORGAN J, RIVIERJ, VALE W, KOOB GF: Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology (1985) 86:170–174.
   PubMed Web of Science ®Google Scholar
• DE BOER SE KATZ JL, VALENTINO RJ: Common mechanisms underlying the proconflict effects of corticotropin-releasing factor, a benzodiazepine inverse agonist and electric foot-shock. J. Pharmacol Exp. Titer. (1992) 262:335–342.
   PubMed Web of Science ®Google Scholar
• COLE BJ, KOOB GF: Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. Pharmacol Exp. Titer. (1988) 247:902–910.
   PubMed Web of Science ®Google Scholar
• GUPTA P, BRUSH FR: Differential behavioral and endocrinological effects of corticotropin-releasing hormone (CRH) in the Syracuse high- and low-avoidance rats. Harm. Behav. (1998) 34:262–267.
   PubMed Web of Science ®Google Scholar
• HEINRICHS SC, JOPPA M: Dissociation of arousal-like from anxiogenic-like actions of brain corticotropin-releasing factor receptor ligands in rats. Behav. Brain Res.. (2001) 122:43–50.
   PubMed Web of Science ®Google Scholar
• SHERMAN JE, KALIN NH: ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. Pharmacol Biochem. Behav. (1988) 30:801–807.
   PubMed Web of Science ®Google Scholar
• DUNN AJ, FILE SE: Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Donn. Behav. (1987) 21:193–202.
   Google Scholar
• MELE A, CABIB S, OLIVERIO A, MELCHIORRI P, PUGLISI-ALLEGRA S: Effects of corticotropin releasing factor and sauvagine on social behavior of isolated mice. Peptides (1987) 8:935–938.
   PubMed Web of Science ®Google Scholar
• ELKABIR DR, WYATT ME, VELLUCCI SV, HERBERT J: The effects of separate or combined infusions of corticotrophin-releasing factor and vasopressin either intraventricularly or into the amygdala on aggressive and investigative behaviour in the rat. Regal. Pept. (1990) 28:199–214.
   PubMed Web of Science ®Google Scholar
• PILLAR G, MALHOTRA A, LAVIE P: Post-traumatic stress disorder and sleep - what a nightmare! Sleep Med. Rev (2000) 4:183–200.
   Google Scholar
• McCURRY SM, GIBBONS LE, LOGSDON RG, TERI L: Anxiety and nighttime behavioral disturbances. Awakenings in patients with Alzheimer's disease.J Gerontol Nurs. (2004) 30:12–20.
   Google Scholar
• SMOLLER JVV, ROSENBAUM JF, BIEDERMAN J et al.: Association of a genetic marker at the corticotropin-releasing hormone locus with behavioral inhibition. Biol. Psychiatry (2003) 54:1376–1381.
   PubMed Web of Science ®Google Scholar
• ALBACH F, EVERAERD W: Posttraumatic stress symptoms in victims of childhood incest. Psychother. Psychosom. (1992) 57:143–151.
   PubMed Web of Science ®Google Scholar
• BRITTON DR, KOOB GE RIVIER J, VALE W: Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Se/. (1982) 31:363–367.
   PubMed Web of Science ®Google Scholar
• DIAMANT M, CROISET G, DE WIED D: The effect of corticotropin-releasing factor (CRF) on autonomic and behavioral responses during shock-prod burying test in rats. Peptides (1992) 13:1149–1158.
   PubMed Web of Science ®Google Scholar
• PELTON GH, LEE Y, DAVIS M: Repeated stress, like vasopressin, sensitizes the excitatory effects of corticotropin releasing factor on the acoustic startle reflex. Brain Res. (1997) 778:381–387.
   PubMed Web of Science ®Google Scholar
• SWERDLOW NR, BRITTON KT, KOOB GF: Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by a-helical CRF (9-41). Neuropsychophannacology (1989) 2:285–292.
   PubMed Web of Science ®Google Scholar
• DE JONGH R, GROENINK L, VAN DER GJ, OLIVIER B: Light-enhanced and fear-potentiated startle: temporal characteristics and effects of alpha-helical corticotropin-releasing hormone. Biol. Psychiatry (2003) 54:1041–1048.
   PubMed Web of Science ®Google Scholar
• RASSNICK S, KOOB GE GEYER MA: Responding to acoustic startle during chronic ethanol intoxication and withdrawal. Psychopharmacology (1992) 106:351–358.
   PubMed Web of Science ®Google Scholar
• SWERDLOW NR, GEYER MA, VALE WW, KOOB GF: Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (1986) 88:147–152.
   PubMed Web of Science ®Google Scholar
• LIANG KC, MELIA KR, CAMPEAU S et al.: Lesions of the central nucleus of the amygdala, but not the paraventricular nucleus of the hypothalamus, block the excitatory effects of corticotropin-releasing factor on the acoustic startle reflex. Neurosci. (1992) 12:2313–2320.
   PubMed Web of Science ®Google Scholar
• LIANG KC, MELIA KR, MISERENDINO MJ et al.: Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. " Neurosci. (1992) 12:2303–2312.
   Google Scholar
• RISBROUGH VB, HAUGER RL, PELLEYMOUNTER MA, GEYER MA: Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (2003) 170:178–187.
   PubMed Web of Science ®Google Scholar
• GRILLON C, MORGAN CA, III, DAVIS M, SOUTHWICK SM: Effect of darkness on acoustic startle in Vietnam veterans with PTSD. Am. I Psychiatry (1998) 155:812–817.
   PubMed Web of Science ®Google Scholar
• GRILLON C, MORGAN CA 3rd, DAVIS M, SOUTHWICK SM: Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder. Biol. Psychiatry (1998) 44:1027–1036.
   PubMed Web of Science ®Google Scholar
• GRILLON C, DIERKER L, MERIKANGAS KR: Fear-potentiated startle in adolescent offspring of parents with anxiety disorders. Biol. Psychiatry (1998) 44:990–997.
   PubMed Web of Science ®Google Scholar
• FARADAY MM, O'DONOGHUE VA, GRUNBERG NE: Effects of nicotine and stress on startle amplitude and sensory gating depend on rat strain and sex. Pharmacol Biochem. Behav. (1999) 62:273–284.
   PubMedGoogle Scholar
• SIPOS ML, BAUMAN RA, WIDHOLM JJ, KANT GJ: Behavioral effects Of 8-0H-DPAT in chronically stressed male and female rats. Pharmacol Biochem. Behav. (2000) 66:403–411.
   PubMed Web of Science ®Google Scholar
• FARADAY MM: Rat sex and strain differences in responses to stress. Physiol Behav. (2002) 75:507–522.
   PubMed Web of Science ®Google Scholar
• CONTI LH, MURRY JD, RUIZ MA, PRINTZ MP: Effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in two rat strains. Psychopharmacology (2002) 161:296–303.
   PubMed Web of Science ®Google Scholar
• BRAFF DL, GEYER MA, SWERDLOW NR: Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (2001) 156:234–258.
   PubMed Web of Science ®Google Scholar
• MIYAZATO H, SKINNER RD, GARCIA-RILL E: Locus coeruleus involvement in the effects of immobilization stress on the p13 midlatency auditory evoked potential in the rat. Frog. Neuropsychopharmacol Biol. Psychiatry (2000) 24:1177–1201.
   PubMed Web of Science ®Google Scholar
• GRILLON C, MORGAN CA, SOUTHWICK SM, DAVIS M, CHARNEY DS: Baseline startle amplitude and prepulse inhibition in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res. (1996) 64:169–178.
   PubMed Web of Science ®Google Scholar
• LUDEWIG S, LUDEWIG K, GEYER MA, HELL D, VOLLENWEIDER FX: Prepulse inhibition deficits in patients with panic disorder. Depress. Anxieg,. (2002) 15:55–60.
   PubMed Web of Science ®Google Scholar
• SCHALL U, SCHON A, ZERBIN D, EGGERS C, OADES RD: Event-related potentials during an auditory discrimination with prepulse inhibition in patients with schizophrenia, obsessive-compulsive disorder and healthy subjects. hat. Neurosci. (1996) 84:15–33.
   PubMed Web of Science ®Google Scholar
• GHISOLFI ES, MARGIS R, BECKER J et al.: Impaired P50 sensory gating in post-traumatic stress disorder secondary to urban violence. hall. Psychophysiol (2004) 51:209–214.
   PubMed Web of Science ®Google Scholar
• NEYLAN TC, FLETCHER DJ, LENOCI M et al.: Sensory gating in chronic posttraumatic stress disorder: reduced auditory P50 suppression in combat veterans. Biol. Psychiatry (1999) 46:1656–1664.
   PubMed Web of Science ®Google Scholar
• SKINNER RD, RASCO LM, FITZGERALD J et al.: Reduced sensory gating of the P1 potential in rape victims and combat veterans with posttraumatic stress disorder. Depress. Anxiety (1999) 9:122–130.
   PubMedGoogle Scholar
• GILLETTE GM, SKINNER RD, RASCO LM et al.: Combat veterans with posttraumatic stress disorder exhibit decreased habituation of the P1 midlatency auditory evoked potential. Life Sci. (1997) 61:1421–1434.
   PubMed Web of Science ®Google Scholar
• VELDHUIS HD, DE WIED D: Differential behavioral actions of corticotropin-releasing factor (CRF). Pharmacol Biochem. Behav. (1984) 21:707–713.
   PubMed Web of Science ®Google Scholar
• TARJAN E, DENTON DA, WEISINGER RS: Corticotropin-releasing factor enhances sodium and water intake/ excretion in rabbits. Bradt Res. (1991) 542:219–224.
   PubMed Web of Science ®Google Scholar
• KALIN NH, SHELTON SE, BARKSDALE CM: Behavioral and physiologic effects of CRH administered to infant primates undergoing maternal separation. Neuropsychopharmacology (1989) 2:97–104.
   PubMed Web of Science ®Google Scholar
• STROME EM, WHELER GH, HIGLEY JD et al.: Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates. Proc. Natl. Acad. SclUSA (2002) 99:15749–15754.
   PubMed Web of Science ®Google Scholar
• BARRETT JE, ZHANG L, AHLERS ST, WOJNICKI FH: Acute and chronic effects of corticotropin-releasing factor on schedule-controlled responding and neurochemistry of pigeons. Pharmacol. Exp. The]: (1989) 250:788–794.
   PubMed Web of Science ®Google Scholar
• ZHANG L, BARRETT JE: Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons. Biol. Psychiatry (1990) 27:953–967.
   PubMed Web of Science ®Google Scholar
• LEE Y, DAVIS M: Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. Neurosci. (1997) 17:6434–6446.
   PubMed Web of Science ®Google Scholar
• LIANG KC, LEE EH: Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory avoidance learning and reduce exploratory behavior in rats. Psychopharmacology (1988) 96:232–236.
   PubMed Web of Science ®Google Scholar
• SAJDYK TJ, SCHOBER DA, GEHLERT DR, SHEKHAR A: Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav. Bradt Res. (1999) 100:207–215.
   PubMed Web of Science ®Google Scholar
• RADULOVIC J, RUHMANN A, LIEP OLD T, SPIESS J: Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. Neurosci. (1999) 19:5016–5025.
   PubMed Web of Science ®Google Scholar
• KASK A, NGUYEN HP, PABST R, VON HORSTEN S: Neuropeptide Y Y1 receptor-mediated amdolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience (2001) 104:799–806.
   PubMed Web of Science ®Google Scholar
• MARTINS AP, MARRAS RA, GUIMARAES FS: Amdogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal grey. Neuroreport (1997) 8:3601–3604.
   PubMed Web of Science ®Google Scholar
• BUTLER PD, WEISS JM, STOUT JC, NEMEROFF CB: Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. Neurosci. (1990) 10:176–183.
   PubMed Web of Science ®Google Scholar
• DEAK T, NGUYEN KT, EHRLICH AL et al.: The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology (1999) 140:79–86.
   PubMed Web of Science ®Google Scholar
• ZORRILLA EP, SCHULTEIS G, ORMSBY A et al.: Urocortin shares the memory modulating effects of corticotropin-releasing factor (CRF): mediation by CRF1 receptors. Brazil Res. (2002) 952:200–210.
   Web of Science ®Google Scholar
• STECKLER T, HOLSBOER F: Interaction between the cholinergic system and CRH in the modulation of spatial discrimination learning in mice. Bradt Res. (2001) 906:46–59.
   PubMed Web of Science ®Google Scholar
• FISHER LA, BROWN MR: Corticotropin-releasing factor and angiotensin II: comparison of CNS actions to influence neuroendocrine and cardiovascular function. Brazil Res. (1984) 296:41–47.
   Web of Science ®Google Scholar
• LENZ HJ, RAEDLER A, GRETEN H, BROWN MR: CRF initiates biological actions within the brain that are observed in response to stress. Am. Physiol (1987) 252:R34–R39.
   PubMed Web of Science ®Google Scholar
• GROSSKREUTZ CL, BRODY MJ: Regional hemodynamic responses to central administration of corticotropin-releasing factor (CRF). Bradt Res. (1988) 442:363–367.
   PubMed Web of Science ®Google Scholar
• OVERTON JM, FISHER LA: Central nervous system actions of corticotropin-releasing factor on cardiovascular function in the absence of locomotor activity. Regal. Pept. (1989) 25:315–324.
   PubMed Web of Science ®Google Scholar
• RICHTER RM, MULVANY MJ: Comparison of hCRF and oCRF effects on cardiovascular responses after central, peripheral, and M vitro application. Peptides (1995) 16:843–849.
   PubMed Web of Science ®Google Scholar
• DIAMANT M, DE WIED D: Autonomic and behavioral effects of centrally administered corticotropin-releasing factor in rats. Endocrinology (1991) 129:446–454.
   PubMed Web of Science ®Google Scholar
• KORTE SM, EISINGA W, TIMMERMAN W, NYAKAS C, BOHUS B: Behavioral and cardiac responses after intracerebroventricular corticotropin-releasing hormone (CRH) administration: role of adrenal cortical hormones. Horm. Behav. (1992) 26:375–384.
   PubMed Web of Science ®Google Scholar
• DIAMANT M, KASHTANOV SI, FODOR M, DE WIED D: Corticotropin-releasing factor induces differential behavioral and cardiovascular effects after intracerebroventricular and lateral hypothalamic/perifornical injections in rats. Neuroendocrinology (1992) 56:750–760.
   PubMed Web of Science ®Google Scholar
• NIJSEN MJ, CROISET G, STAM R et al: The role of the CRH Type 1 receptor in autonomic responses to corticotropin-releasing hormone in the rat. Neuropsychopharmacology (2000) 22:388–399.
   PubMed Web of Science ®Google Scholar
• IRWIN M, HAUGER R, BROWN M: Central corticotropin-releasing hormone activates the sympathetic nervous system and reduces immune function: increased responsivity of the aged rat. Endocrinology (1992) 131:1047–1053.
   PubMed Web of Science ®Google Scholar
• LINTHORST AC, FLACHSKAMM C, HOPKINS SJ et al: Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, and cytokine responses to a systemic inflammatory
   Google Scholar
• �� challenge..! Neurosci. (1997) 17:4448–4460.
   Google Scholar
• BUWALDA B, DE BOER SF, VAN KALKEREN AA, KOOLHAAS JM: Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneumendocrinology (1997) 22:297–309.
   PubMed Web of Science ®Google Scholar
• ROTHWELL NJ, HARD WICK A, LEFEUVRE RA, CROSBY SR, WHITE A: Central actions of CRF on thermogenesis are mediated by pro-opiomelanocortin products. Brain Res. (1991) 541:89–92.
   PubMed Web of Science ®Google Scholar
• DE FANTI BA, MARTINEZ JA: Central urocortin activation of sympathetic-regulated energy metabolism in Wistar rats. Brain Res.(2002) 930:37–41.
   PubMed Web of Science ®Google Scholar
• GRILL HJ, MARKISON S, GINSBERG A, KAPLAN JM: Long-term effects on feeding and body weight after stimulation of forebrain or hindbrain CRH receptors with urocortin. Brain Res. (2000) 867:19–28.
   PubMed Web of Science ®Google Scholar
• BROWN MR, GRAY TS, FISHER LA: Corticotropin-releasing factor receptor antagonist: effects on the autonomic nervous system and cardiovascular function. Regul Pept. (1986) 16:321–329.
   PubMed Web of Science ®Google Scholar
• SOLMAZ M, KAVUK I, SAYAR K: Psychological factors in the irritable bowel syndrome. Ear: J. Med. Res. (2003) 8:549–556.
   PubMed Web of Science ®Google Scholar
• HAZLETT-STEVENS H, CRASKE MG, MAYER EA, CHANG L, NALIBOFF BD: Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. " Psychosom. Res. (2003) 55:501–505.
   PubMed Web of Science ®Google Scholar
• SYKES MA, BLANCHARD EB, LACKNER J, KEEFER L, KRASNER S: Psychopathology in irritable bowel syndrome: support for a psychophysiological model." Behav. Med. (2003) 26:361–372.
   PubMed Web of Science ®Google Scholar
• GARAKANI A, WIN T, VIRK S et al: Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am. J. The]: (2003) 10:61–67.
   PubMedGoogle Scholar
• TACHÈ Y, MARTINEZ V, MILLION M, WANG L: Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. Physiol Gastrointest. Liver Physiol (2001) 280:G173–G177.
   Google Scholar
• MILLION M, MAILLOT C, SAUNDERS P et al.: Human urocortin II, a new CRF-related peptide, displays selective CRF2-mediated action on gastric transit in rats. Am. Physiol Gastrointest. Liver Physiol (2002) 282:G34–G40.
   PubMed Web of Science ®Google Scholar
• TACHÈ Y, MARTINEZ V, MILLION M, MAILLOT C: Role of corticotropin-releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. Eur. J. Stag. (2002) 587(Suppl.):168–170.
   Google Scholar
• BREMNER JD, LICINIO J, DARNELL A et al.: Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am. Psychiatry (1997) 154:624–629.
   PubMed Web of Science ®Google Scholar
• ��Examines the possibility of changes incentral CRF secretion or postsynaptic function in human anxiety disorders.
   Google Scholar
• BAKER DG, WEST SA, NICHOLSON WE et al: Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am. J. Psychiatric (1999) 156:585–588.
   PubMed Web of Science ®Google Scholar
• ��See [190].
   Google Scholar
• SAUTTER FJ, BISSETTE G, WILEY J et al.: Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol. Psychiatry (2003) 54:1382–1388.
   PubMed Web of Science ®Google Scholar
• ��See [190].
   Google Scholar
• KAYE WH, GWIRTSMAN HE, GEORGE DT et al.: Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J Clin. Endocrinol Metab. (1987) 64:203–208.
   PubMed Web of Science ®Google Scholar
• ��See [190].
   Google Scholar
• HOTTA M, SHIBASAKI T, MASUDA A et al.: The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients.' Clin. Endocrinol Metab. (1986) 62:319–324.
   Google Scholar
• ��See [190].
   Google Scholar
• ADINOFF B, ANTON R, LINNOILA M et al.: Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmacology (1996) 15:288-295. See [190].
   Google Scholar
• ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CB: The role of corticotropin-releasing factor in depression and anxiety disorders. Endocrinol (1999) 160:1–12.
   Web of Science ®Google Scholar
• ��See [190].
   Google Scholar
• NEMEROFF CB, OWENS MJ, BISSETTE G, ANDORN AC, STANLEY M: Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry (1988) 45:577–579.
   PubMed Web of Science ®Google Scholar
• ��See [190].
   Google Scholar
• MERALI Z, DU L, HRDINA P et al: Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. Neurosci. (2004) 24:1478–1485.
   PubMed Web of Science ®Google Scholar
• ��See [190].
   Google Scholar
• ALTEMUS M, PIGOTT T, KALOGERAS KT et al.: Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch. Gen. Psychiatry (1992) 49:9–20.
   PubMed Web of Science ®Google Scholar
• ��See [190]. zoo. FOSSEY MD, LYDIARD RB, BALLENGER JC et al.: Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol. Psychiatry (1996) 39:703–707.
   Google Scholar
• ��See [190].
   Google Scholar
• ALTEMUS M, SWEDO SE, LEONARD HL et al.: Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch. Gen. Psychiatry (1994) 51:794–803.
   PubMed Web of Science ®Google Scholar
• ��See [190]. zoz. CHAPPELL P, LECKMAN J, GOODMAN W et al.: Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol. Psychiatry (1996) 39:776–783.
   Google Scholar
• ��See [190].
   Google Scholar
• SWEDO SE, LEONARD HL, KRUESI MJ et al.: Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch. Gen. Psychiatry(1992) 49:29–36.
   PubMed Web of Science ®Google Scholar
• ��See [190].
   Google Scholar
• BANKI CM, KARMACSI L, BISSETTE G, NEMEROFF CB: Cerebrospinal fluid neuropeptides in mood disorder and dementia. j. Affect. Disord. (1992) 25:39–45.
   PubMed Web of Science ®Google Scholar
• ��See [190].
   Google Scholar
• JOLKKONEN J, LEPOLA U, BISSETTE G, NEMEROFF C, RIEKKINEN P: CSF corticotropin-releasing factor is not affected in panic disorder. Biol. Psychiatry(1993) 33:136–138.
   PubMed Web of Science ®Google Scholar
• ��See [190]. zos. BERRETTINI WH, NURNBERGER JI, JR., ZERBE RL et al: CSF neuropeptides in euthymic bipolar patients and controls. Br.Psychiatry (1987) 150:208–212.
   Google Scholar
• ��See [190].
   Google Scholar
• VIETA E, MARTINEZ-DE-OSABA MJ, COLOM F et al.: Enhanced corticotropin response to corticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients. Psycho]. Med. (1999) 29:971–978.
   PubMed Web of Science ®Google Scholar
• ��See [190]. zos. RYBAKOWSKI JK, TWARDOWSKA K: The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. Psychiatr. Res. (1999) 33:363–370.
   Google Scholar
• ��See [190]. zos. SCHMIDER J, LAMMERS CH, GOTTHARDT U et al.: Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol. Psychiatry(1995) 38:797–802.
   Google Scholar
• ��See [190].
   Google Scholar
• GILMOR ML, SKELTON KH, NEMEROFF CB, OWENS MJ: The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. Pharinacol Exp. Ther. (2003) 305:434–439.
   PubMed Web of Science ®Google Scholar
• RIVIERJ, RIVIER C, VALE W: Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science (1984) 224:889–891.
   PubMed Web of Science ®Google Scholar
• ��First reported synthesis of a receptorsubtype non-selective CRF receptor partial agonist, a-helical-CRF9_41.
   Google Scholar
• MENZAGHI F, HOWARD RL, HEINRICHS SC et al.: Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. Pharinacol Exp. Ther. (1994) 269:564–572.
   PubMed Web of Science ®Google Scholar
• ��First behavioural characterisation of the anxiolytic-like and anti-arousing-like effects of a competitive peptide non-selective CRF receptor full antagonist, D-Phe CRF1241.
   Google Scholar
• GULYAS J, RIVIER C, PERRIN M et al.: Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc. Natl. Acad. Sci. USA (1995) 92:10575–10579.
   PubMed Web of Science ®Google Scholar
• RIVIER J, GULYAS J, CORRIGAN A et al.: Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat. I Med. Chem. (1998) 41:5012–5019.
   PubMed Web of Science ®Google Scholar
• SHIBASAKI T, YAMAUCHI N, HOTTA M et al.: Brain corticotropin-releasing hormone increases arousal in stress. Bradt Res. (1991) 554:352–354.
   PubMed Web of Science ®Google Scholar
• SHIBASAKI T, IMAKI T, HOTTA M, LING N, DEMURA H: Psychological stress increases arousal through brain corticotropin-releasing hormone without significant increase in adrenocorticotropin and catecholamine secretion. Bradt Res. (1993) 618:71–75.
   PubMed Web of Science ®Google Scholar
• SHIBASAKI T, IMAKI T, HOTTA M, LING N, DEMURA H: Restraint changes pentobarbital-induced sleeping time in rats: evidence that arousal is modulated by brain corticotropin-releasing hormone and opioid in stress. Regal Pep] (1994) 51:141–149.
   PubMed Web of Science ®Google Scholar
• OJIMA K, MATSUMOTO K, TOHDA M, WATANABE H: Hyperactivity of central noradrenergic and CRF systems is involved in social isolation-induced decrease in pentobarbital sleep. Bradt Res. (1995) 684:87–94.
   PubMed Web of Science ®Google Scholar
• BERRIDGE CW, DUNN AJ: A corticotropin-releasing factor antagonist reverses the stress-induced changes of exploratory behavior in mice. Horm. Behav. (1987) 21:393–401.
   PubMed Web of Science ®Google Scholar
• MENZAGHI F, RASSNICK S, HEINRICHS S et al.: The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann. NY Acad. Sri. (1994) 739:176–184.
   PubMed Web of Science ®Google Scholar
• HEINRICHS SC, MENZAGHI F, PICH EM et al.: Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology (1994) 11:179–186.
   PubMed Web of Science ®Google Scholar
• HEINRICHS SC, PICH EM, MICZEK KA, BRITTON KT, KOOB GF: Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. (1992) 581:190–197.
   PubMed Web of Science ®Google Scholar
• RASSNICK S, HEINRICHS SC, BRITTON KT, KOOB GF: Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. (1993) 605:25–32.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI LK, KALIN NH, BAKER EW: Corticotropin-releasing factor antagonist attenuates defensive-withdrawal behavior elicited by odors of stressed conspecifics. Behav. Neurosci. (1990) 104:386–389.
   PubMed Web of Science ®Google Scholar
• TUCCI S, CHEETA S, SETH P, FILE SE: Corticotropin releasing factor antagonist, a-helical CRF(9-41), reverses nicotine-induced conditioned, but not unconditioned, anxiety. Psychopharmacology (2003) 167:251–256.
   PubMed Web of Science ®Google Scholar
• DEVRIES AC, PERT A: Conditioned increases in amdogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor. Psychopharmacology (1998) 137:333–340.
   PubMed Web of Science ®Google Scholar
• VALDEZ GR, ZORRILLA EP, ROBERTS AJ, KOOB GF: Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol (2003) 29:55–60.
   PubMed Web of Science ®Google Scholar
• SPINA MG, BASSO AM, ZORRILLA EP et al.: Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology (2000) 22:230–239.
   PubMed Web of Science ®Google Scholar
• KALIN NH, SHERMAN JE, TAKAHASHI LK: Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Bradt Res. (1988) 457:130–135.
   PubMed Web of Science ®Google Scholar
• KALIN NH, TAKAHASHI LK: Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems. Brazil Res. (1990) 509:80–84.
   Web of Science ®Google Scholar
• KORTE SM, KORTE-BOUWS GA, BOHUS B, KOOB GF: Effect of corticotropin-releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats. Physiol Behav. (1994) 56:115–120.
   PubMed Web of Science ®Google Scholar
• BASSO AM, SPINA M, RIVIER J, VALE W, KOOB GF: Corticotropin-
   Google Scholar
• �� releasing factor antagonist attenuates the `amdogenic-like' effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (1999) 145:21–30.
   Google Scholar
• JASNOW AM, BANKS MC, OWENS EC, HUHMAN KL: Differential effects of two corticotropin-releasing factor antagonists on conditioned defeat in male Syrian hamsters (Mesocricetus auratus). Brain Res. (1999) 846:122–128.
   PubMed Web of Science ®Google Scholar
• SWIERGIEL AH, TAKAHASHI LK, RUBIN WW, KALIN NH: Antagonism of corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing in rats. Bradt Res. (1992) 587:263–268.
   PubMed Web of Science ®Google Scholar
• SWIERGIEL AH: Effects of infusion of corticotropin-releasing factor antagonist into the locus coeruleus on freezing behavior and brain catecholamines in rats. Acta Neurobiol Exp. (2003) 63:9–16.
   PubMed Web of Science ®Google Scholar
• NIJSEN MJ, CROISET G, DIAMANT M, DE WIED D, WIEGANT VM: CRH signalling in the bed nucleus of the stria terminalis is involved in stress-induced cardiac vagal activation in conscious rats. Neuropsychopharmacology (2001) 24:1–10.
   PubMed Web of Science ®Google Scholar
• SWIERGIEL AH, TAKAHASHI LK, KALIN NH: Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Bradt Res. (1993) 623:229–234.
   PubMed Web of Science ®Google Scholar
• NAKAMORI T, MORIMOTO A, MURAKAMI N: Effect of a central CRF antagonist on cardiovascular and thermoregulatory responses induced by stress or IL-1 beta. Am..! Physiol (1993) 265:R834–R839.
   PubMed Web of Science ®Google Scholar
• MORIMOTO A, NAKAMORI T, MORIMOTO K, TAN N, MURAKAMI N: The central role of corticotrophin-releasing factor (CRF-41) in psychological stress in rats.' Physiol (1993) 460:221–229.
   Web of Science ®Google Scholar
• NIJSEN MJ, CROISET G, DIAMANT M et al.: Endogenous corticotropin-releasing hormone inhibits conditioned-fear-induced vagal activation in the rat. Ear. Pharmacol (2000) 389:89–98.
   PubMed Web of Science ®Google Scholar
• WILLIAMS CL, PETERSON JM, VILLAR RG, BURKS TF: Corticotropin-releasing factor directly mediates colonic responses to stress. Am. J. Physiol (1987) 253:G582–G586.
   PubMed Web of Science ®Google Scholar
• GUE M, JUNIEN JL, BUENO L: Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology (1991) 100:964–970.
   PubMed Web of Science ®Google Scholar
• MONNIKES H, SCHMIDT BG, TACHE Y: Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor. Gastroenterology (1993) 104:716–723.
   PubMed Web of Science ®Google Scholar
• BONAZ B, TACHE Y: Water-avoidance stress-induced c-fos expression in the rat brain and stimulation of fecal output: role of corticotropin-releasing factor. Brain Res. (1994) 641:21–28.
   PubMed Web of Science ®Google Scholar
• MARTINEZ V, RIVIER J, WANG L, TACHE Y: Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. Pharmacol Exp. Ther. (1997) 280:754–760.
   PubMed Web of Science ®Google Scholar
• MONNIKES H, SCHMIDT BG, RAYBOULD HE, TACHE Y: CRF in the paraventricular nucleus mediates gastric and colonic motor response to restraint stress. Am. J. Physic] (1992) 262:G137–G143.
   Web of Science ®Google Scholar
• STENZEL-POORE MP, HEINRICHS SC, RIVEST S, KOOB GE VALE WW: Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of amdogenic behavior. J. Neurosci. (1994) 14:2579–2584.
   PubMed Web of Science ®Google Scholar
• ��First report on the anxiogenic-like effectsof transgenic CRF overexpression in the mouse.
   Google Scholar
• KASK A, RAGO L, HARRO J: a-helical CRF(9-41) prevents amdogenic-like effect of NPY Y1 receptor antagonist BIBP3226 in rats. Neuroreport (1997) 8:3645–3647.
   PubMed Web of Science ®Google Scholar
• BIRO E, SARNYAI Z, PENKE B, SZABO G, TELEGDY G: Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology (1993) 57:340–345.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G, PERRAULT G, SANGER DJ: Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents: Comparison with diazepam and buspirone. Psychopharmacology (1998) 138:55–66.
   PubMed Web of Science ®Google Scholar
• BRITTON KT, LEE G, VALE W, RIVIER J, KOOB GF: Corticotropin releasing factor (CRF) receptor antagonist blocks activating and `anxiogenic' actions of CRF in the rat. Brain Res. (1986) 369:303–306.
   PubMed Web of Science ®Google Scholar
• BRITTON KT, AKWA Y, SPINA MG, KOOB GF: Neuropeptide Y blocks amdogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides (2000) 21:37–44.
   PubMed Web of Science ®Google Scholar
• IVERSEN SD: Animal models of anxiety and benzodiazepine actions. Arzneimittelforschung (1980) 30:862–868.
   PubMed Web of Science ®Google Scholar
• HEINRICHS SC, KLAASSEN A, KOOB GF et al.: Corticotropin-releasing factor receptor blockade enhances conditioned aversive properties of cocaine in rats. Psychopharmacology (1998) 136:247–255.
   PubMed Web of Science ®Google Scholar
• MILLAN MJ: The neurobiology and control of anxious states. Frog. Neurobiol (2003) 70:83–244.
   Google Scholar
• ��An recent exhaustive preclinical review ofthe neurochemistry and neurobiology of anxiety and its treatment.
   Google Scholar
• ETTENBERG A, GEIST TD: Animal model for investigating the amdogenic effects of self-administered cocaine. Psychopharmacology (1991) 103:455–461.
   PubMed Web of Science ®Google Scholar
• DAVIS M, WALKER DL, MYERS KM: Role of the amygdala in fear extinction measured with potentiated startle. Ann. NY Acad. Sci. (2003) 985:218–232.
   PubMed Web of Science ®Google Scholar
• ROOZENDAAL B, BRUNSON KL, HOLLOWAY BL, MeGAUGH JL, BARAM TZ: Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc. Nati Acad. Sci. USA (2002) 99:13908–13913.
   PubMed Web of Science ®Google Scholar
• SAUVAGE M, STECKLER T: Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei-potential implication for arousal and attention. Neuroscience (2001) 104:643–652.
   PubMed Web of Science ®Google Scholar
• SARNYAI Z, HOHN J, SZABO G, PENKE B: Critical role of endogenous corticotropin-releasing factor (CRF) in the mediation of the behavioral action of cocaine in rats. Life Sci. (1992) 51:2019–2024.
   PubMed Web of Science ®Google Scholar
• CONTARINO A, DELLU F, KOOB GF et al.: Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. (1999) 835:1–9.
   PubMed Web of Science ®Google Scholar
• TIMPL P, SPANAGEL R, SILLABER I et al.: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. (1998) 19:162–166.
   PubMed Web of Science ®Google Scholar
• ��One of the first two reports to reveal theanxiolytic-like phenotype of CRF1-deficient mice.
   Google Scholar
• MULLER MB, ZIMMERMANN S, SILLABER I et al: Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci (2003) 6:1100–1107.
   PubMed Web of Science ®Google Scholar
• �First demonstration that deletion of limbic CRF1 receptors without deletion of pituitary CRF1 receptors was sufficient to produce an anxiolytic-like phenotype, reinforcing the importance of extrahypothalarnic CRF1 neurotransmission in anxious states.
   Google Scholar
• LIEBSCH G, LAND GRAF R, ENGELMANN M, LORSCHER P, HOLSBOER F: Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. " Psychiam Res. (1999) 33:153–163.
   PubMed Web of Science ®Google Scholar
• LIEBSCH G, LAND GRAF R, GERSTBERGER R et al.: Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regal Pept. (1995) 59:229–239.
   PubMed Web of Science ®Google Scholar
• SKUTELLA T, PROBST JC, RENNER U, HOLSBOER F, BEHL C: Corticotropin-releasing hormone receptor (Type I) antisense targeting reduces anxiety. Neuroscience. (1998) 85:795–805.
   PubMed Web of Science ®Google Scholar
• HEINRICHS SC, LAPSANSKY J, LOVENBERG TW, DE SOUZA EB, CHALMERS DT: Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate amdogenic-like behavior. Regal Pept. (1997) 71:15–21.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI LK: Role of CRF(1) and CRF(2) receptors in fear and anxiety. Neurosci. Biobehav. Rev (2001) 25:627–636.
   PubMed Web of Science ®Google Scholar
• OWENS MJ, NEMEROFF CB: Preclinical and clinical studies with corticotropin-releasing factor: implications for affective disorders. Psychopharmacol Bull. (1988) 24:355–359.
   PubMed Web of Science ®Google Scholar
• HEINRICHS SC, TACHE Y: Therapeutic potential of CRF receptor antagonists: a gut-brain perspective. Expert Opin. Investig. Drugs (2001) 10:647–659.
   PubMed Web of Science ®Google Scholar
• CHRISTOS TE, ARVANITIS A: Corticotrophin-releasing factor receptor antagonists. Expert Opin. Ther. Patents (1998) 8:143–152.
   Web of Science ®Google Scholar
• AYALA AR, WAND GS: CRH receptor antagonists: advances and prospective. Expert Opin. Ther. Patents (2000) 10:67–74.
   Web of Science ®Google Scholar
• LANIER M, WILLIAMS JP: Small molecule corticotropin-releasing factor antagonists. Expert Opin. Ther. Patents (2002) 12:1619–1630.
   Web of Science ®Google Scholar
• �Excellent review on the structure-activity relationships of recently developed small-molecule CU' receptor antagonists.
   Google Scholar
• HOD GETTS KJ, YOON T, HUANG J et at.: 2-Ary1-3,6-dialky1-5-dialkylaminopyrimidin-4-ones as novel CRF-1 receptor antagonists. Bioorg. Med. Chem. Lett (2003) 13:2497–2500.
   Google Scholar
• GULLY D, GESLIN M, SERVA L et al: 4-(2-Chloro-4-methoxy-5-methylpheny1)- N-R1S)-2-cyclopropyl 1 (3 fluoro 4 methylphenyl) ethyl] 5-methyl-N- (2-propyny1)-1,3-thiazol-2-amine hydrochloride (55R125543A): a potent and selective corticotrophin-releasing factori receptor antagonist. I. Biochemical and pharmacological characterization. Pharmacol Exp. Ther. (2002) 301:322–332.
   PubMed Web of Science ®Google Scholar
• WILSON DM, TERMIN AP, MAO L et al.: Arylamidrazones as novel corticotropin releasing factor receptor antagonists.' Med. Chem. (2002) 45:2123–2126.
   Web of Science ®Google Scholar
• ��A novel selective CRF1 receptor antagonistsmall-molecule pharmacophore.
   Google Scholar
• LUTHIN DR, RABINOVICH AK, BHUMRALKAR DR et al: Synthesis and biological activity of ox0-7H-benzorelperimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists. Bioorg. Med. Chem. Lett. (1999) 9:765–770.
   PubMed Web of Science ®Google Scholar
• ��An underexplored mixed CRE1/CRE2receptor antagonist small-molecule pharmacophore.
   Google Scholar
• NAKAZATO A, KUMAGAI T, OKUBO T et al.: Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factorl receptor antagonists. Bioorg. Med. Chem. (2000) 8:1183–1193.
   PubMed Web of Science ®Google Scholar
• McCLUSKEY A, KELLER PA, MORGAN J, GARNER J: Synthesis, molecular modeling and biological activity of methyl and thiomethyl substituted pyrimidines as corticotropin releasing hormone type 1 antagonists. Org. Biomol Chem. (2003) 1:3353–3361.
   PubMed Web of Science ®Google Scholar
• DUBOWCHIK GM, MICHNE JA, ZUEV D et al.: 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy. Bioorg. Med. Chem. Lett. (2003) 13:3997–4000.
   PubMed Web of Science ®Google Scholar
• HOARE SR, SULLIVAN SK, LING N, CROWE PD, GRIGORIADIS DE: Mechanism of corticotropin-releasing factor Type I receptor regulation by nonpeptide antagonists. Ma Pharmacol (2003) 63:751–765.
   PubMed Web of Science ®Google Scholar
• �A report demonstrating that CRF1 antagonists, which adhere to the classical pharmacophore, are non-competitive antagonists.
   Google Scholar
• LIAW CW, GRIGORIADIS DE, LORANG MT, DE SOUZA EB, MAKI RA: Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Endocrinol (1997) 11:2048–2053.
   Web of Science ®Google Scholar
• GILLIGAN PJ, BALDAUF C, COCUZZA A et at.: The discovery of 4-(3-pentylamino)-2,7-dimethyl 8 (2 methy1-4- methoxyphenyl) -pyrazolo--pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg. Med. Chem. (2000) 8:181–189.
   Google Scholar
• MONASSIER L, BOUSQUET P: Sigma receptors: from discovery to highlights of their implications in the cardiovascular system. Fundam. Clin. Pharmacol (2002) 16:1–8.
   PubMed Web of Science ®Google Scholar
• WAN CP, LAU BH: Neuropeptide Y receptor subtypes. Life Se/. (1995) 56:1055–1064.
   PubMed Web of Science ®Google Scholar
• HSIN LW, TIAN X, WEBSTER EL et al: CRHR1 receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone Type 1 receptor antagonists. Bioorg. Med. Chem. (2002) 10:175–183.
   PubMed Web of Science ®Google Scholar
• CHORVAT RJ, BAKTHAVATCHALAM R, BECK JP et al.: Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-,
   Google Scholar
• �� imidazo-, and pyrrolopyrimidines and -pyridines. j. Med. Chem. (1999) 42:833–848.
   Google Scholar
• ARVANITIS AG, RESCINITO JT, ARNOLD CR et al.: Imidazo, 5-clpyridines as corticotropin releasing factor receptor ligands. Bioorg. Med. Chem. Lett. (2003) 13:129–131.
   PubMed Web of Science ®Google Scholar
• ARVANITIS AG, RESCINITO JT, ARNOLD CR et al.: Imidazo, 5-blpyridines as corticotropin releasing factor receptor ligands. Bioorg. Med. Chem. Lett. (2003) 13:125–128.
   PubMed Web of Science ®Google Scholar
• WILCOXEN K, HUANG CQ, McCARTHY JR, GRIGORIADIS DE, CHEN C: Synthesis of 3- phenylpyrazolo [4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists. Bioorg. Med. Chem. Lett. (2003) 13:3367–3370.
   PubMed Web of Science ®Google Scholar
• HUANG CQ, WILCOXEN K, McCARTHY JR et al.: Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factorl (CRF1) receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:3375–3379.
   PubMed Web of Science ®Google Scholar
• HUANG CQ, WILCOXEN K, McCARTHY JR et al.: Synthesis of 1-methy1-3-phenylpyrazolo [4, 3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists. Bioorg. Med. Chem. Lett (2003) 13:3371–3374.
   PubMed Web of Science ®Google Scholar
• HEINRICHS SC, DE SOUZA EB, SCHULTEIS G, LAPSANSKY JL, GRIGORIADIS DE: Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor Type I receptor selective antagonist. Neuropsychopharmacology(2002) 27:194–202.
   PubMed Web of Science ®Google Scholar
• HE L, GILLIGAN PJ, ZACZEK R et al.: 4- (1,3-Dimethoxyprop-2-ylamino)-2,7-dimethy1-8-(2, 4- dichlorophenyl)pyrazolo triazine: a potent, orally bioavailable CRF(1) receptor antagonist.' Med. Chem. (2000) 43:449–456.
   Google Scholar
• ��One of the two first demonstrations oforal, anxiolytic-like efficacy of small-molecule CRF1 receptor antagonists in primates.
   Google Scholar
• HABIB KE, WELD KP, RICE KC et al.: Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Nati Acad. Sci. USA (2000) 97:6079–6084.
   PubMed Web of Science ®Google Scholar
• ��One of the two first demonstrations oforal, anxiolytic-like efficacy of small-molecule CRF1 receptor antagonists in primates.
   Google Scholar
• KELLER C, BRUELISAUER A, LEMAIRE M, ENZ A: Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metal,. Dispos. (2002) 30:173–176.
   PubMed Web of Science ®Google Scholar
• LI YW, HILL G, WONG H et al.: Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and amdolytic efficacy. Pharmacol. Exp. TheL (2003) 305:86–96.
   PubMed Web of Science ®Google Scholar
• �An excellent demonstration and discussion of the relations of free plasma antagonist levels to brain antagonist accumulation to brain CRF1 receptor occupancy to anxiolytic-like efficacy. One of the first studies to focus on the interfering effects of high plasma protein binding on CRF1 antagonist efficacy.
   Google Scholar
• HANSCH C, BJORKROTH JP, LEO A: Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. Pharm. Sci. (1987) 76:663–687.
   PubMed Web of Science ®Google Scholar
• LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deify. Rev (2001) 46:3–26.
   PubMed Web of Science ®Google Scholar
• �A review extending upon the 'rule of 5' criteria for drug discovery and development, a heuristic that emphasises the importance of physiochemical indices of solubility and permeability.
   Google Scholar
• OPREA TI, DAVIS AM, TEAGUE SJ, LEESON PD: Is there a difference between leads and drugs? A historical perspective. Chem. Inf. Comput. Sci. (2001) 41:1308–1315.
   PubMedGoogle Scholar
• �A review that provides additional physiochemical criteria for selecting candidate lead molecules for further drug optimisation.
   Google Scholar
• TEAGUE SJ, DAVIS AM, LEESON PD, OPREA T: The design of leadlike combinatorial libraries. Angew. Chem. hat. Ed Engi (1999) 38:3743-3748. A review that provides additional physiochemical criteria, more stringent than Lipinski's 'rule of 5,' for selecting candidate lead molecules suitable for further optimisation to produce a drug with the desired characteristics.
   Google Scholar
• BANG LM, CHAPMAN TM, GOA KL: Lercanidipine : a review of its efficacy in the management of hypertension. Drugs. (2003) 63:2449–2472.
   PubMed Web of Science ®Google Scholar
• LIN JH, LU AY: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev (1997) 49:403–449.
   PubMed Web of Science ®Google Scholar
• WENINGER SC, DUNN AJ, MUGLIA LJ et al.: Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc. Nati Acad. ScL USA (1999) 96:8283–8288.
   PubMed Web of Science ®Google Scholar
• LELAS S, WONG H, LI YVV et al.: Amdolytic-like effects of the CRF1 antagonist DMP904 administered acutely or chronically at doses occupying central CRF1 receptors in rats. Pharmacol. Exp. The]: (2004) 309:293–302.
   Google Scholar
• HOTTA M, SHIBASAKI T, ARAI K, DEMURA H: Corticotropin-releasing factor receptorType 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. Brain Res. (1999) 823:221–225.
   PubMed Web of Science ®Google Scholar
• ZORRILLA E, FEKETE E, MASON BJ et al.: CRF1 antagonists for anxiety. Eur: Neuropsychopharmacol. (2003) 13:130.
   Google Scholar
• GRIEBEL G, SIMIAND J, STEINBERG R et al.: 4-(2-Chloro-4-methoxy-5-methylpheny1)-N-[(1.5)-2-cyclopropyl 1 (3 fluoro-4- methylphenyl) ethyl] 5-methyl-N- (2-propyny1)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. Pharmacol. Exp. The]: (2002) 301:333–345.
   Google Scholar
• ARAI K, OHATA H, SHIBASAKI T: Non-peptidic corticotropin-releasing hormone receptor Type 1 antagonist reverses restraint stress-induced shortening of sodium pentobarbital-induced sleeping time of rats: evidence that an increase in arousal induced by stress is mediated through CRH receptor type 1. Neurosci. Lett. (1998) 255:103–106.
   PubMed Web of Science ®Google Scholar
• LANCEL M, MULLER-PREUSS P, WIGGER A, LAND GRAF R, HOLSBOER F: The CRH1 receptor antagonist R121919 attenuates stress- elicited sleep disturbances in rats, particularly in those with high innate anxiety. I Psychiatr. Res. (2002) 36:197–208.
   PubMed Web of Science ®Google Scholar
• LELAS S, ZELLER KL, WARD KA, MCELROY JF: The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepwdde in rats. Psychopharmacology (2003) 166:408–415.
   PubMed Web of Science ®Google Scholar
• ARBORELIUS L, SKELTON KH, THRIVIKRAMAN KV et al.: Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. Pharmacol Exp. Ther. (2000) 294:588–597.
   PubMed Web of Science ®Google Scholar
• OHATA H, ARAI K, SHIBASAKI T: Effect of chronic administration of a CRF(1) receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress. Ear. Pharmacol (2002) 457:201–206.
   PubMed Web of Science ®Google Scholar
• GUTMAN DA, OWENS MJ, SKELTON KH, THRIVIKRAMAN KV, NEMEROFF CB: The corticotropin-releasing factorl receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. Pharmacol Exp. Ther: (2003) 304:874–880.
   Google Scholar
• JAMES SE, GHOSH SJ, MONTGOMERIE J, PHILP BM, DZIEWULSKI P: Survival of a 75% burn in a patient with longstanding Addison's disease. Burns (2002) 28:391–393.
   PubMed Web of Science ®Google Scholar
• SIBBALD WJ, SHORT A, COHEN MP, WILSON RF: Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections. Ann. Surg. (1977) 186:29–33.
   Google Scholar
• LU L, LIU Z, HUANG M, ZHANG Z: Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes. Neurochem. (2003) 84:1378–1386.
   PubMed Web of Science ®Google Scholar
• STINUS L, CADOR M, ZORRILLA EP, KOOB GF: Buprenorphine and a CRF antagonist block the acquisition of opiate withdrawal-induce conditioned place aversion in rats. Neuropsychopharmacology (In press).
   Google Scholar
• BROADBEARJH, WINGER G, RICE KC, WOODS JH: Antalarmin, a putative CRH-RI antagonist, has transient reinforcing effects in rhesus monkeys. Psychopharmacology (2002) 164:268–276.
   PubMed Web of Science ®Google Scholar
• BROADBEAR JH, WINGER G, RIVIER JE, RICE KC, WOODS JH: Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology (2004) 29(6):1112–21
   PubMed Web of Science ®Google Scholar
• ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. Psychiatc Res. (2000) 34:171–181.
   PubMed Web of Science ®Google Scholar
• ��The first publication of efficacy-relateddata from an open-label trial with a selective CRF1 receptor antagonist.
   Google Scholar
• HELD K, KUNZEL H, ISING M et al.: Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. I Psychiatc Res. (2004) 38:129–136.
   PubMed Web of Science ®Google Scholar
• KUNZEL HE, ZOBEL AW, NICKEL T et al.: Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. Psychiatr. Res. (2003) 37:525–533.
   Google Scholar
• MARTARELLO L, KILTS CD, ELY T et al.: Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nucl. Med. Biol. (2001) 28:187–195.
   PubMed Web of Science ®Google Scholar
• ZHANG G, HUANG N, LI YW et al: Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+1-)-N [2-methyl-4-methoxyphenyl] 1 (1 (methoxymethyl) propyl) -6 -methyl-1H-1, 2, 3 -triazolo, 5 pyridin- 4-amine ([3H]SNO03) for corticotropin-releasing factorl receptors. Pharmacol Exp. Ther: (2003) 305:57–69.
   Google Scholar
• �One of two publications to first reveal viable, more hydrophilic radiotracers for positron emission tomography (PET) and single photon emission-computed tomography (SPECT) imaging studies of CRF1 receptor binding in vivo.
   Google Scholar
• JAGODA E, CONTOREGGI C, LEE MJ et al.: Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.1. Med. Chem. (2003) 46:3559–3562.
   Google Scholar
• �One of two publications to first reveal viable, more hydrophilic radiotracers for PET and SPECT imaging studies of CRF1 receptor binding in vivo.
   Google Scholar
• CHAKI S, NAKAZATO A, KENNIS L et al.: Anxiolytic- and antidepressant-like profile of a new CRF(1) receptor antagonist, R278995/CRA0450. Ear. .1 Pharmacol (2004) 485:145–158.
   Google Scholar
• �A report of a novel CRF1 receptor antagonist with cross-affinity for 61-receptors that also has more potent motoric side effects than previously disclosed structures. The results urge the importance of detailing unintended affinities of CRF1 drug candidates, including the interaction of these small-molecules with the 61-receptor.
   Google Scholar
• BURT DR, CREESE I, SNYDER SH: Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science (1977) 196:326–328.
   PubMed Web of Science ®Google Scholar
• LAVREYSEN H, LE POUL E, VAN GOMPEL P et al: Supersensitivity of human metabotropic glutamate la receptor signaling in L929sA cells. MM. Pharmacol (2002) 61:1244–1254.
   PubMed Web of Science ®Google Scholar
• YUAN J, GULIANELLO M, DE LOMBAERT S et al.: 3-Aryl pyrazolo [4,3-dlpyrimidine derivatives: Nonpeptide CRF-1 antagonists. Bioorg. Med. Chem. Lett. (2002) 12:2133–2136.
   Google Scholar
• GILLIGAN PJ, FOLMER BK, HARTZ RA et al: Pyrazolo-[1,5-a]-1,3,5-triazine corticotropin-releasing factor (CRF) receptor ligands. Bioorg. Med. Chem. (2003) 11:4093–4102.
   PubMed Web of Science ®Google Scholar
• SEYMOUR PA, SCHMIDT AW, SCHULZ DW: The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: A review. CNS Drug Rev (2003) 9:57–96.
   PubMedGoogle Scholar
• GILLIGAN PJ, ROBERTSON DW, ZACZEK R: Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. Med. Chem. (2000) 43:1641–1660.
   Web of Science ®Google Scholar
• McCARTHY JR, HEINRICHS SC, GRIGORIADIS DE: Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Carr. Pharm. Des. (1999) 5:289–315.
   PubMed Web of Science ®Google Scholar
• MILLION M, GRIGORIADIS DE, SULLIVAN S et al: A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res. (2003) 985:32–42.
   PubMed Web of Science ®Google Scholar
• ROSSANT CJ, PINNOCK RD, HUGHES J, HALL MD, McNULTY S: Corticotropin-releasing factor type 1 and type 2a receptors regulate phosphorylation of calcium/cyclic adenosine 3',5'-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology (1999) 140:1525–1536.
   PubMed Web of Science ®Google Scholar
• MACKAY KB, BOZIGIAN H, GRIGORIADIS DE et al.: Neuroprotective effects of the CRF1 antagonist R121920 after permanent focal ischemia in the rat. Cereb. Blood Flow Metab. (2001) 21:1208–1214.
   PubMed Web of Science ®Google Scholar
• GILLIGAN PJ, HARTIG PR, ROBERTSON DW, ZACZEK R: Corticotrophin-releasing hormone (CRH) receptors and the discovery of selective non-peptide CRH antagonists. Ann. Rep. Med. Chem. (1997) 32:41–50.
   Web of Science ®Google Scholar
• MILLAN MJ, BROCCO M, GOBERT A et al.: Amdolytic properties of the selective, non-peptidergic corticotropin-releasing factor (CRF)1 antagonists, CP154,526 and DMP 695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology (2001) 25:585–600.
   PubMed Web of Science ®Google Scholar
• KECK M, WELT T, WIGGER A et al: The amdolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Ear: Neurosci. (2001) 13:373–380.
   PubMed Web of Science ®Google Scholar
• McELROY JF, WARD KA, ZELLER KL et al.: The CRF(1) receptor antagonist DMP696 produces amdolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Psychopharmacology (2002) 165:86–92.
   PubMed Web of Science ®Google Scholar
• HARRO J, TONISSAAR M, ELLER M: The effects of CPA 1000, a non-peptide antagonist of corticotropin- releasing factor receptor Type 1, on adaptive behaviour in the rat. Neuropeptides (2001) 35:100–109.
   PubMed Web of Science ®Google Scholar
• MACIAG CM, DENT G, GILLIGAN P et al.: Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation. Neuropsychopharmacology(2002) 26:574–582.
   PubMed Web of Science ®Google Scholar
• OVERSTREET DH, KNAPP DJ, BREESE GR: Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF(1) receptors. Pharmacol Biochem. Behav. (2004) 77:405–413.
   PubMed Web of Science ®Google Scholar
• KEHNE JH, COVERDALE S, McCLOSKEY TC, HOFFMAN DC, CASSELLA JV: Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization amdolytic test in rat pups. Neuropharmacol (2000) 39:1357–1367.
   PubMed Web of Science ®Google Scholar
• KIKUSUI T, TAKEUCHI Y, MORI Y: Involvement of corticotropin-releasing factor in the retrieval process of fear-conditioned ultrasonic vocalization in rats. Physic] Behav. (2000) 71:323–328.
   PubMed Web of Science ®Google Scholar
• HIKICHI T, AKIYOSHI J, YAMAMOTO Y et al: Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatly (2000) 33:189–193.
   PubMed Web of Science ®Google Scholar
• HO SP, TAKAHASHI LK, LIVANOV V et al.: Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Bradt Res. Ma Brain Res.. (2001) 89:29–40.
   PubMedGoogle Scholar
• CHEN YL, MANSBACH RS, WINTER SM et al.: Synthesis and oral efficacy of a 4- (butylethylamino)pyrrolo [2,3-c4pyrimidine: a centrally active corticotropin-releasing factorl receptor antagonist. Med. Chem. (1997) 40:1749–1754.
   Web of Science ®Google Scholar
• LUNDKVIST J, CHAT Z, TEHERANIAN R et al: A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits amdolytic-like activity. Ear: Pharmacol (1996) 309:195–200.
   PubMed Web of Science ®Google Scholar
• HOPE PJ, TURNBULL H, FARR S et al: Peripheral administration of CRF and urocortin: effects on food intake and the HPA axis in the marsupial Sminthopsis crassicaudata. Peptides (2000) 21:669–677.
   PubMed Web of Science ®Google Scholar
• BORNSTEIN SR, WEBSTER EL, TORPY DJ et al: Chronic effects of a nonpeptide corticotropin-releasing hormone Type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology (1998) 139:1546–1555.
   PubMed Web of Science ®Google Scholar
• WONG ML, WEBSTER EL, SPOKES H et al.: Chronic administration of the non-peptide CRH Type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sri. (1999) 65:PL53-PL58.
   Google Scholar
• http://thomsoncurrentdrugs.com/products/ iddb/ Thomson Current Drugs, Investigational Drugs Database, Thomson Scientific, London, 2003.
   Google Scholar